Anzeige
+++Der nächste Milliardenmarkt?: Dieser Small Cap positioniert sich jetzt mittendrin+++
PortfolioPlus
Portfolio-Tracker – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
Original-Research

Limes Schlosskliniken AG (von NuWays AG): BUY 01.09.2026, 09:00 Uhr von EQS Research Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Limes Schlosskliniken 540,00 EUR +0,47 % Lang & Schwarz

Original-Research: Limes Schlosskliniken AG - from NuWays AG

01.09.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to Limes Schlosskliniken AG

Company Name: Limes Schlosskliniken AG
ISIN: DE000A0JDBC7
 
Reason for the research: Update
Recommendation: BUY
Target price: EUR 810
Target price on sight of: 12 months
Last rating change:
Analyst: Philipp Sennewald

H1 confirms the case, FCF set to grow strongly; chg.

Yesterday, LIMES published its H1'25 report, showing continued top-line expansion thanks to the new clinics as well as strong profitability despite the ramp-up of those. In detail:

H1 sales grew 29.2% yoy to € 29.7m, carried by 31,552 billed patient days (+17.5% yoy) and a 10% rise in revenue per day to € 942. New clinics Abtsee and Bergisches Land contributed € 7.4m, and management expects the largest incremental growth from these two sites going forward. PRC Zurich grew 25% yoy with demand into H2 unchanged and a standing waiting list. Mind you, Zurich is the ultra-premium offering, carrying both the highest rate per day and the least cyclicality. Fürstenhof and Mecklenburgische Schweiz ran below last year's occupancy, with a return to good utilisation expected by mid-year.

EBITDA of € 7.0m (+12%) implies a 23.6% margin, down from 27.1%. The dilution is almost purely ramp-up related with personnel expenses up 29% to € 13.5m as headcount went from 237 to 314, and rent climbing 84% to € 3.5m as six sites carried a full period of fixed costs against occupancy still building at two of them. Marketing of € 2.4m (+36%) reflects launch spend that should taper. What matters more is that Abtsee is already positive at the pre-tax line and Bergisches Land positive on EBITDA, both within six months of operation. Against a portfolio where earlier openings took materially longer to break even, this is the clearest validation yet: when LIMES opens new locations, they fill quickly. With the cost base now largely in place for all six clinics, incremental occupancy should drop through at high marginal margins from here.

Cash generation inflected sharply. Operating cash flow rose 73% to € 5.5m, while capex fell to € 0.7m from € 4.0m, depicting a normalization after the build-out. FCF of € 4.8m compares to € -0.7m in H1'25, implying a strong conversion of 69% of EBITDA. This fully confirms our case, that a mature LIMES portfolio converts a large chunk it earns into cash. The asset-light model carries no property, maintenance capex runs at roughly € 100k per clinic, and working capital needs are minimal. Every clinic that finishes ramping therefore adds cash, not just revenue, exactly what makes the Italian, and possible further, expansion affordable without touching the balance sheet.

Looking at H2, a failure at the pool technology of the Mecklenburg clinic is set to keep that site below potential until reinstallation is finalized by YE. This aside, the setup remains strong. Fürstenhof is back to good utilisation, Zurich enters H2 with unchanged demand and a waiting list, and both new clinics are ready to scale. Adding to this is Boccella, which remains on track, with final documents expected by year-end and the licence application to follow over the winter, adding € 15m post ramp-up sales with the opening expected for Summer 2027. With a proven clinic blueprint and a structurally undersupplied market, we would not rule out further European sites thereafter. At 5.1x FY27e EV/EBITDA, the shares still do not price in that potential, in our view.

Reiterate BUY with an unchanged € 810 PT based on DCF.

You can download the research here: limes-schlosskliniken-ag-2026-09-01-update-en-b5587
For additional information visit our website: https://www.nuways-ag.com/research

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2391436  01.09.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Ihre Lieblingsaktie geschenkt

BörsenNEWS.de und Smartbroker+ starten gemeinsam eine exklusive Bonus-Aktion. Eröffnen Sie bis 31.08.2026 ein Depot bei Smartbroker+ und erhalten als Willkommensgeschenk einen Anteil ausgewählter Aktien im Wert von 50 Euro!.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer